TY - JOUR
T1 - Minoxidil therapy in children with severe hypertension
AU - Lietman, Paul S.
AU - Pennisi, Alfred J.
AU - Takahashi, Masato
AU - Bernstein, Bram H.
AU - Singsen, Bernhard H.
AU - Uittenbogaart, Christel
AU - Ettenger, Robert B.
AU - Malekzadeh, Mohammad H.
AU - Hanson, Virgil
AU - Fine, Richard N.
N1 - Funding Information:
From the Department of Pediatrics, University of Southern California School of Medicine," and the Dialysis and Transp\[unt Program, Division of Cardiology, Division of Rheumatology and Rehabilitation, Childrens Hospital Of Log Angeles. Supported in part by Childrens Heart Foundation of Southern Calffbrnia. *Reprint address: Childrens Hospital of Los Angeles, P.O. Box 54700 Terminal Annex, Los Angeles, CA 90054.
PY - 1977/5
Y1 - 1977/5
N2 - Six children, from 1.3 to 18 years of age, with severe hypertension associated with the hemolytic uremic syndrome, periarteritis, and renal transplant rejection received minoxidil, an antihypertensive agent, for three to 36 weeks. All had severe hypertension resistant to oral antihypertensive medications; five required frequent intravenous diazoxide therapy prior to minoxidil therapy. The mean pretreatment systolic and diastolic blood pressures were 176 and 117 mm Hg, respectively. Following treatment, the mean systolic and diastolic blood pressures were 133 and 82 mm Hg, respectively. Concomitant antihypertensive medications were decreased in all six patients once optimal blood pressure control was obtained. The initial dosage of minoxidil was 0.1 to 0.2 mg/kg/day; maximal dosage for blood pressure was 0.3 to 1.4 mg/kg/day. Major complications of therapy were fluid retention and hirsutism. Transient asymptomatic pericardial effusions occurred in two patients. Three patients on prolonged minoxidil therapy had persistent increases in right ventricular end diastolic diameters. Minoxidil is an effective oral antihypertensive agent for treatment of severe hypertension in pediatric patients. Avoidance of fluid retention is mandatory to prevent congestive heart failure.
AB - Six children, from 1.3 to 18 years of age, with severe hypertension associated with the hemolytic uremic syndrome, periarteritis, and renal transplant rejection received minoxidil, an antihypertensive agent, for three to 36 weeks. All had severe hypertension resistant to oral antihypertensive medications; five required frequent intravenous diazoxide therapy prior to minoxidil therapy. The mean pretreatment systolic and diastolic blood pressures were 176 and 117 mm Hg, respectively. Following treatment, the mean systolic and diastolic blood pressures were 133 and 82 mm Hg, respectively. Concomitant antihypertensive medications were decreased in all six patients once optimal blood pressure control was obtained. The initial dosage of minoxidil was 0.1 to 0.2 mg/kg/day; maximal dosage for blood pressure was 0.3 to 1.4 mg/kg/day. Major complications of therapy were fluid retention and hirsutism. Transient asymptomatic pericardial effusions occurred in two patients. Three patients on prolonged minoxidil therapy had persistent increases in right ventricular end diastolic diameters. Minoxidil is an effective oral antihypertensive agent for treatment of severe hypertension in pediatric patients. Avoidance of fluid retention is mandatory to prevent congestive heart failure.
UR - http://www.scopus.com/inward/record.url?scp=0017361156&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017361156&partnerID=8YFLogxK
U2 - 10.1016/S0022-3476(77)81260-2
DO - 10.1016/S0022-3476(77)81260-2
M3 - Article
C2 - 323442
AN - SCOPUS:0017361156
SN - 0022-3476
VL - 90
SP - 813
EP - 819
JO - The Journal of pediatrics
JF - The Journal of pediatrics
IS - 5
ER -